Opinion: The end to animal testing marks the beginning of better biomedicine
No longer will our medicines be gated through animals, but rather through entirely human systems — leading to breakthrough options for the humans that need them.
The Food and Drug Administration’s recent decision to phase out animal use in preclinical testing of monoclonal antibodies — and eventually other drugs —with more advanced, human-relevant methods marks a transformative shift with profound implications for drug development. The FDA has now officially recognized that advancing science and technology have pushed us across a threshold: Animal models have become obsolete.
We are now moving away from animal testing toward surrogate systems based on human biology. No longer will our medicines be gated through animals, but rather through entirely human systems — leading to breakthrough options for the humans that need them.
